Company intelligence / Profile preview

EpimAb Biotherapeutics

Ownership: Private
Development stage: Phase 2

Overview

EpimAb has multiple clinical-stage assets with promising results. EMB-06 (BCMA/CD3) showed positive Phase I results for multiple myeloma presented at ASH 2025. EMB-01 (EGFR/cMET) is in Phase I/II trials for GI cancers. The company has successfully licensed EMB-06 ex-China rights to Vignette Bio.

Therapeutic areas: OncologyImmunology
Modalities: Bispecific antibodiesMultispecific antibodiesT cell engagers
Industry: Biotech

Drug pipeline

13 assets

emb-01

12 more assets in the full pipeline.

Request access →

Partnerships

Vignette Bio (acquired by Candid Therapeutics)Medigene AG

Beyond the preview

Go deeper on EpimAb Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpimAb Biotherapeutics.

Explore the full profile